Skip to main content

Evolocumab Side Effects

Medically reviewed by Philip Thornton, DipPharm. Last updated on Jan 16, 2023.

Applies to evolocumab: parenteral solution for injection.

Side effects include:

Adverse effects (reported in >5% of adults with primary hyperlipidemia): Nasopharyngitis, upper respiratory tract infection, influenza, back pain, injection site reactions (e.g., erythema, pain, bruising).

Adverse effects (reported in >5% of adults with established cardiovascular disease): Diabetes mellitus, nasopharyngitis, upper respiratory tract infection.

For Healthcare Professionals

Applies to evolocumab: subcutaneous solution.


The more commonly reported adverse reactions have included nasopharyngitis, upper respiratory tract infection, back pain, and injection site reactions.


Common (1% to 10%): Hypersensitivity reactions (including rash, eczema, erythema, urticaria)

Postmarketing reports: Angioedema[Ref]


Common (1% to 10%): Hypertension[Ref]


Common (1% to 10%): Diarrhea, gastroenteritis, nausea (1.8%)[Ref]


Common (1% to 10%): Urinary tract infection[Ref]


Common (1% to 10%): Injection site reaction (including erythema, pain, bruising)[Ref]


Common (1% to 10%): Back pain, myalgia, musculoskeletal pain, arthralgia (1.8%)[Ref]

Nervous system

Common (1% to 10%): Headache, dizziness

Uncommon (0.1% to 1%): Neurocognitive events (0.2%)[Ref]


Common (1% to 10%): Influenza, fatigue (1.6%)

Uncommon (0.1% to 1%): Contusion[Ref]


Common (1% to 10%): Influenza, fatigue (1.6%)

Uncommon (0.1% to 1%): Contusion[Ref]


Rare (less than 0.1%): Development anti-drug antibody

Postmarketing reports: Influenza-like illness[Ref]

Frequently asked questions


1. Product Information. Repatha (evolocumab). Amgen USA. 2015.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.